Ann: Resignation of CEO and Managing Director, page-41

They are hardly at the top of the ladder, and its only the start of the season. They have multiple phase 1 trials to complete, then its on to ph2, and possibly phase 3. This is a multi year play, and they need to keep the funding alive. When you look at her tenure, she's been the CEO of a company that seen its share price go from over 30c to under 3c. I know it's not entirely her fault, but in this biotech winter they've been hit hard, and as a CEO, you are required to take some responsibility. It was not sustainable for a company this small to be paying someone that much in wages. Her commitments to the CR was abysmal. She spoke a good pitch but ultimately her actions (ownership) was saying other things. I respect her but I think ultimately she has done her service here and has been rewarded handsomely. Onwards we go!